Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Indocyanine Green Fluorescence for Intraoperative Tumor Identification During Resection of Pediatric and Adolescent Intra-Abdominal Malignancy: A Prospective Multi-Institutional Observational Study.

Journal of the American College of Surgeons·2026

Same author

Outcomes and Surgical Management of Malignant Rhabdoid Tumor of the Kidney: A Report From the Pediatric Surgical Oncology Research Collaborative.

Pediatric blood & cancer·2026

Same author

International Society of Paediatric Surgical Oncology (IPSO) Minimally Invasive Surgery (MIS) Guidelines.

Ecancermedicalscience·2026

Same author

Developing the research roadmap together: a report from the patient-centered outcome research institute (PCORI) and pediatric surgical oncology research collaborative (PSORC).

Pediatric surgery international·2026

Same author

Survival in children with hepatoblastoma and pulmonary metastatic disease at diagnosis based on extent of metastases and need for surgical clearance.

Journal of pediatric surgery·2026

Same author

Indocyanine green assists with sentinel lymph node mapping in pediatric and adolescent patients: A Pediatric Surgical Oncology Research Collaborative prospective observational study.

Cancer·2026

Same journal

The EXTra-uterine Environment for Neonatal Development (EXTEND) - future treatment for prematurity and potentially other congenital disease.

Seminars in pediatric surgery·2026

Same journal

Appendicitis as a model for pediatric surgical quality improvement and standardization.

Seminars in pediatric surgery·2026

Same journal

From FOB to PICU: military trauma systems that changed pediatrics.

Seminars in pediatric surgery·2026

Same journal

Long-term follow-up after surgery for congenital anomalies: A time to complication analysis.

Seminars in pediatric surgery·2026

Same journal

Radio-surgical decision-making in hepatoblastoma in the post-PHITT era: SIOPEL consensus recommendations.

Seminars in pediatric surgery·2026

Same journal

Seminars in pediatric sugery pediatric metabolic and bariatric surgery.

Seminars in pediatric surgery·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Dec 31, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Recent progress in pediatric soft tissue sarcoma therapy.

Timothy B Lautz¹, Andrea Hayes-Jordan²

¹Division of Pediatric Surgery, Ann & Robert H Lurie Children's Hospital of Chicago, Northwestern University, 225 E Chicago Ave, Box 63, Chicago, IL 60611, United States.

Seminars in Pediatric Surgery

|January 15, 2020

Summary

This summary is machine-generated.

Pediatric soft tissue sarcomas require multimodal therapy. Advances in comprehensive care, particularly surgical techniques, have improved outcomes for children with these rare tumors.

More Related Videos

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Related Experiment Videos

Last Updated: Dec 31, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Area of Science:

Pediatric Oncology
Surgical Oncology
Cancer Therapeutics

Background:

Soft tissue sarcomas in children are diverse tumors with varied clinical presentations and prognoses.
Current treatment paradigms predominantly involve multimodal approaches, including chemotherapy, surgery, and radiation therapy.
Despite significant advancements in supportive care and cooperative group studies, the core chemotherapy regimens have seen limited progress.

Purpose of the Study:

To emphasize the critical role of surgical therapy in managing pediatric soft tissue sarcomas.
To highlight the necessity of a deep understanding of surgical nuances to optimize patient outcomes.
To underscore the importance of minimizing local recurrence and preserving function in affected children.

Main Methods:

Review of current treatment strategies for pediatric soft tissue sarcomas.
Analysis of the impact of multimodal therapy on patient outcomes.
Focus on the principles and techniques of surgical intervention in pediatric sarcoma care.

Main Results:

Comprehensive care improvements, driven by cooperative group studies, have led to better outcomes for children with soft tissue sarcomas.
Surgical intervention plays a pivotal role in achieving local disease control.
Minimizing local failure and functional deficits requires meticulous surgical planning and execution.

Conclusions:

Multimodal therapy remains the cornerstone for treating pediatric soft tissue sarcomas.
Surgical expertise is paramount for achieving optimal oncologic and functional results.
Continued research and adherence to best practices in surgical oncology are essential for improving the long-term well-being of these young patients.